Related Experiment Videos
[Uterine leiomyoma: pathogenesis and treatment]
1Department of Obstetrics and Gynecology, School of Medicine, Shinshu University, Matsumoto.
Nihon Sanka Fujinka Gakkai Zasshi
|August 1, 1992
Summary
Uterine leiomyoma (fibroid) development may stem from fetal smooth muscle cells affected by maternal factors. These cells, influenced by hormones like estrogen and progesterone, grow after menarche and shrink post-menopause.
Area of Science:
- Reproductive biology
- Developmental biology
- Gynecology
Context:
- Uterine leiomyoma pathogenesis remains debated.
- Fetal smooth muscle development differs between endoderm- and mesoderm-derived ducts.
- Mesodermal smooth muscle development is slower, suggesting a longer period of vulnerability.
Purpose:
- To explore the potential origins of uterine leiomyomas from fetal smooth muscle progenitor cells.
- To understand the role of maternal environmental factors and hormonal influences in leiomyoma development.
- To identify potential therapeutic targets based on leiomyoma growth patterns.
Summary:
- Fetal undifferentiated smooth muscle cells in the uterus, with a prolonged developmental period, may be susceptible to maternal environmental factors, becoming leiomyoma progenitor cells.
- These progenitor cells, residing in the myometrium, proliferate post-menarche, driven by estrogen and progesterone, and typically cease growth after menopause.
- Magnetic resonance imaging (MRI) is crucial for diagnosing uterine leiomyomas, providing information on location, number, and characteristics.
Impact:
- Suggests a developmental origin for uterine leiomyomas, shifting focus to early-life factors.
- Highlights hormonal dependence of leiomyomas, supporting hormonal therapies like GnRH analogues.
- Emphasizes the diagnostic importance of MRI in managing uterine leiomyomas.